Thymos Health
Your Rheumatoid Arthritis Journey

Still in pain.
Still switching one drug at a time.
Still no real answers.

You're not alone. This is how rheumatoid arthritis (RA) is typically managed — and an honest look at what that journey costs over time.

1.3M Americans are living with rheumatoid arthritis.1
3× more common in women than men.1
36 months is the median delay to rheumatology referral.2
39 sick days are lost per year, on median.3

How rheumatoid arthritis is typically treated

Most insurance plans require step therapy — starting with conventional drugs before approving biologics or targeted therapies. Joint damage can begin within the first two years of disease.

Mark where you are in your journey and we'll show you the full picture.

Step 1: Your doctor starts you on Methotrexate
Otrexup / Rasuvo / generic — weekly oral or subcutaneous injection
What your doctor says
"This is the anchor drug for rheumatoid arthritis. It slows disease progression by suppressing your immune system. Give it 3–6 months for full effect."
~30% discontinue in year 14
Inefficacy in ~40% at 6 months5
3–6 months to see full response4
Annual drug cost (generic oral) ~$200–$800
Providers seen before this was prescribed
How long were you on Methotrexate?
What happened?
Required monitoring: CBC, liver enzymes, creatinine — every 4–8 weeks year 1
~$600–$1,400 in labs
~40% inadequate responders move to Step 2
Step 2: You graduate to Adalimumab
Humira / biosimilars (Hadlima, Hyrimoz, Cyltezo) — SC injection every 2 weeks
What your doctor says
"This biologic targets TNF-alpha, a key driver of joint inflammation. Most patients see meaningful results within 12–16 weeks."
~20–25 clinic encounters in the year before starting15
~30% never respond at all6
~38% develop antidrug antibodies within 1 year7
Annual cost before insurance (AWP) ~$103,000
How long were you on Adalimumab?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$20,600
~38% form antibodies to anti-TNF — many switch to Step 3
Step 3: You move to Upadacitinib
Rinvoq — once-daily oral JAK1 inhibitor (15 mg)
What your doctor says
"This is a targeted pill that works inside the cell rather than blocking a protein."
~60% do not achieve full remission8
Rising risk of blood clots, cancer, and acute cardiovascular events9
Annual cost before insurance (AWP) ~$64,000
How long have you been on Upadacitinib?
What happened?
Your coinsurance for this drug
Your estimated annual out-of-pocket for this drug
$12,800
60% of non-responders require joint surgery
When joint damage has progressed too far Joint replacement surgery
Total knee or hip arthroplasty — elective or urgent
What Your Doctor says
"The medications have slowed progression, but the joint damage already done is irreversible. Replacement will significantly improve your pain and function."
~20% lifetime risk of knee or hip replacement10
2× higher than the general population10
17% undergo orthopedic intervention within 5 years11
$30K–$50K
Hospital + surgeon cost for total knee or hip replacement
3–5 days
Hospital stay (joint replacement)
3–6 mo
Full functional recovery timeline
~8%
Revision surgery within 10 years
Recovery timeline
Hospital stay — knee or hip replacement 2–5 days
Weight-bearing / walking with assist Day 1–2 post-op
Return to desk work 4–6 weeks
Physical / manual labor 3–6 months
Driving resumption (hip replacement) 4–6 weeks
30-day readmission rate 5–10%
Periprosthetic infection risk (rheumatoid arthritis patients) 1.5–2.5× higher
What changes long-term
🔁 Surgery doesn't stop rheumatoid arthritis progression. Joint replacement addresses mechanical damage but does not modify the underlying disease. Untreated rheumatoid arthritis will continue to attack other joints — cervical spine, shoulders, wrists, and small joints of the hands are all at risk. Ongoing DMARD therapy is typically maintained post-operatively.
🦠 Elevated infection risk. rheumatoid arthritis patients on immunosuppressive therapy have a 1.5–2.5× higher rate of periprosthetic joint infection than osteoarthritis patients. Biologic DMARDs and JAK inhibitors are typically held 1–5 half-lives before elective surgery and restarted after wound healing — a window requiring close coordination with your rheumatologist.12
🧠 Mental health comorbidity is under-addressed. Major depressive disorder affects ~16.8% of rheumatoid arthritis patients — 2–3× the general population rate of 6.6%.13 Anxiety disorders affect an additional 13.5% on top of that. Depression independently predicts worse pain scores, reduced treatment adherence, and higher healthcare costs — and is rarely screened for at rheumatology visits.
❤️ Cardiovascular risk doubles. rheumatoid arthritis carries a cardiovascular risk equivalent to type 2 diabetes — including 2× the rate of myocardial infarction and a 70% increased risk of stroke vs. age-matched controls.14 This is driven by the cumulative inflammatory burden and is rarely discussed proactively in a rheumatology visit.
🦴 Lymphoma risk up to 26×. rheumatoid arthritis is associated with a markedly elevated risk of haematological malignancies, particularly lymphoma — driven by cumulative inflammatory load.14 Patients with uncontrolled disease for longer periods carry disproportionately higher risk.
⚠ Perioperative DMARD management is complex
Guidelines from ACR/AAHKS recommend holding biologics and JAK inhibitors before elective arthroplasty. The timing varies by drug half-life. This coordination requires explicit planning with your rheumatologist — it is not automatic and not always initiated. Bring it up early if you are considering surgery.

What rheumatoid arthritis is really costing you

Your copay isn't the whole story. Rheumatoid arthritis imposes costs through drugs, lost income, and — for roughly 1 in 5 patients — major joint replacement surgery the healthcare system never puts on the same receipt.

Based on your journey above–adjust the numbers to match your situation.
Work & Income Loss
Sick days missed in the last 12 months
Your hourly wage (for lost income calculation)
$
Joint Replacement Surgery
~20% of rheumatoid arthritis patients will have a knee or hip replacement in their lifetime. If you've had one — or are planning one — include it here.10
Have you had joint replacement surgery?
Your estimated total cost of rheumatoid arthritis $0
Drug out-of-pocket costs $0
Lost income (sick days) $0
Reduced productivity (presenteeism) $0
66% of employed rheumatoid arthritis patients report work loss — median 39 sick days/yr3 Drug out-of-pocket costs based on your coinsurance selection for it above (or a typical default if you haven't reached it yet).
The Other Side of the Bill

What your insurer is paying

Rheumatoid arthritis imposes a substantial and rising cost on commercial insurers. Biologic and targeted synthetic drugs — not the joint replacement surgery patients often fear most — are the dominant driver, and step therapy requirements delay rather than reduce the cumulative spend.

Annual Payer Perspective — Commercial Insurance
What your health plan spends on your rheumatoid arthritis care each year
Based on your drug journey above · All figures reflect payer (insurer) paid portion, not patient out-of-pocket cost.
Estimated annual payer cost for your rheumatoid arthritis care $0
Biologic / targeted DMARD spend (payer portion ~80% of AWP)
Adalimumab AWP ~$103,000/yr; upadacitinib AWP ~$64,000/yr — biologics are the dominant driver of total rheumatoid arthritis spend8
$0
Non-drug medical costs (rheumatologist, labs, imaging, ED)
Patients accumulate a mean of 20–25 outpatient encounters/yr before biologic initiation; ~35% have at least one ED visit15
~$8,200
Biologic-treated rheumatoid arthritis patients cost payers substantially more than those on conventional DMARDs alone — commercial claims analyses report total annual healthcare costs 3–4× higher once a patient escalates to biologic or targeted therapy.18 Roughly 1 in 5 rheumatoid arthritis patients will eventually need a knee or hip replacement, adding a further one-time cost spike on top of ongoing drug spend.10
⚑ Why early, adequate treatment saves payers money
Step therapy requirements mandate a methotrexate trial — and often a first anti-TNF failure — before newer mechanisms are approved, adding months of active, undertreated inflammation. That inflammation accrues irreversible joint damage that drives the ~20% lifetime risk of knee or hip replacement,10 the elevated cardiovascular risk,14 and the work disability3 that make up the majority of the downstream cost burden of rheumatoid arthritis — costs that land on the payer regardless of which drug tier delayed adequate control.
Understanding Your Risk

What the research shows over time

Clinical data on rheumatoid arthritis outcomes can help you have more informed conversations with your care team about what's really at stake with delayed or inadequate disease control.

Based on peer-reviewed clinical data
Long-term outcomes for rheumatoid arthritis patients on step therapy
💊
~40% of rheumatoid arthritis patients on methotrexate fail to achieve adequate response by 6 months — and ~30% discontinue the drug within the first year due to side effects or inefficacy5
🏥
~20% lifetime risk of knee or hip joint replacement — approximately double that of the general population — even in the modern biologic era10
❤️
2× higher myocardial infarction risk and 70% increased stroke risk vs. age-matched controls — its cardiovascular burden is equivalent to type 2 diabetes14
💼
35% of rheumatoid arthritis patients experience significant work disability — with indirect costs from lost productivity estimated to exceed the direct drug costs of treatment3
✦ A different journey exists

Thymos Health offers another way

Conventional rheumatoid arthritis care focuses on managing symptoms through sequential medications. Thymos goes further – synthesizing diagnostics, medical history, symptoms, and lifestyle to understand what's driving your disease and customizes care based on your individual needs.

✓
Root cause treatment — not just another layer of suppression
✓
Whole system autoimmune specialist quarterbacks your labs, your team, your care plan
✓
24/7 personalized support — not just at your next appointment in 3 months
✓
80%+ symptom relief within 3 months across autoimmune conditions
No commitment. Takes 2 minutes.
Sources & Citations ▼
[1] Xu Y, Wu Q. "Prevalence Trend and Disparities in Rheumatoid Arthritis among US Adults, 2005–2018." Journal of Clinical Medicine, 2021;10(15):3289. Approximately 1.3 million US adults (0.6–1.0% of the adult population). Women are affected 3× more commonly than men.
DOI: 10.3390/jcm10153289  ·  PMC: PMC8348893
[2] Almoallim H et al. "Diagnostic and therapeutic delay in Rheumatoid Arthritis patients: Impact on disease outcome." Pakistan Journal of Medical Sciences, 2021. Median lag-2 (delay in consulting a rheumatologist): 30 months (IQR 7.7–72); median diagnostic delay: 12 months; many patients first consulted an orthopedic surgeon (39.2%) or GP (26.5%).
PMC: PMC8281185
[3] Verstappen SMM. "Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism." Best Practice & Research: Clinical Rheumatology, 2015;29(3):495–511. Systematic review: median 66% (range 36–84%) of employed rheumatoid arthritis patients experienced work loss in the prior 12 months, for a median duration of 39 days. Work disability prevalence: ~35%.
DOI: 10.1016/j.berh.2015.05.001  ·  PMID: 16286432
[4] Blum MA et al. "Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review." Journal of Rheumatology, 2016;43(11):1997–2009. MTX persistence rates: 50–94% at 1 year; ~30% discontinue within year 1. Lack of tolerability is the primary reason for withdrawal (23–79% of discontinuations); inefficacy accounts for 6–72%.
DOI: 10.3899/jrheum.151378  ·  URL: jrheum.org
[5] Sergeant JC et al. "Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)." Arthritis Research & Therapy, 2018;20:147. EULAR non-response to MTX at 6 months: ~40% in this prospective UK multi-centre cohort.
DOI: 10.1186/s13075-018-1645-5  ·  PMC: PMC6043972
[6] Fleischmann R et al. "Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)." Annals of the Rheumatic Diseases, 2006;65(8):1088–1094. Primary non-response (ACR20 non-achievement at week 12–16): approximately 30% in anti-TNF-naïve rheumatoid arthritis populations.
DOI: 10.1136/ard.2005.044867  ·  PMID: 16476710
[7] Isaacs JD et al. "Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis." Annals of the Rheumatic Diseases, 2013;72:329–336. Antidrug antibodies detected in 38–43% of patients on infliximab or adalimumab within the first year; antibody formation is strongly associated with loss of clinical response.
DOI: 10.1136/annrheumdis-2012-201516  ·  PMID: 22562974
[8] Fleischmann R et al. (SELECT-COMPARE). "Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-blind, Randomized Controlled Trial." Arthritis & Rheumatology, 2019;71(11):1788–1800. In SELECT-COMPARE: 41% achieved DAS28-CRP remission with UPA 15 mg at week 26, meaning ~59% did not achieve full remission by this criterion; UPA was statistically superior to adalimumab (27% DAS28 remission, p<0.001).
DOI: 10.1002/art.41045  ·  PMID: 31287230
[9] Bhatt DL et al. (ORAL Surveillance). "Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis." New England Journal of Medicine, 2022;386(4):316–326. FDA-mandated post-marketing safety study (ORAL Surveillance): tofacitinib associated with increased risk of MACE, pulmonary embolism, and malignancy vs. anti-TNF comparator in patients aged ≥50 with ≥1 cardiovascular risk factor. FDA subsequently added class-level black box warnings to all approved JAK inhibitors.
DOI: 10.1056/NEJMoa2109927  ·  PMID: 35081280
[10] Hawley S et al. "Lifetime risk of knee and hip replacement following a diagnosis of RA: findings from a cohort of 13,961 patients from England." Rheumatology (Oxford), 2020;59(8):1874–1882. Lifetime risk of knee replacement: ~19%; hip replacement: ~21%; both approximately 2× the risk of the general population. n=13,961.
DOI: 10.1093/rheumatology/kez586  ·  PMID: 31127844  ·  PMC: PMC6848958
[11] Kapral MK et al. "Lower limb joint replacement in rheumatoid arthritis." Open Access Rheumatology, 2012;4:33–44 (citing James et al., Rheumatology, 2003;43:369–376). 17% of rheumatoid arthritis patients underwent an orthopaedic intervention within 5 years of initial diagnosis; over one-third will require a major joint replacement over their lifetime.
PMC: PMC3411461
[12] Goodman SM et al. "2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty." Arthritis & Rheumatology, 2022;74(9):1464–1473. Recommends withholding current-cycle biologic DMARDs before elective THA/TKA; JAK inhibitors held 7 days pre-operatively; NSAIDs held 1 week pre-op.
DOI: 10.1002/art.42107  ·  PMID: 35722709
[13] Matcham F et al. "The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis." Rheumatology (Oxford), 2013;52(12):2136–2148. Pooled prevalence of major depressive disorder in rheumatoid arthritis: 16.8% (95% CI 10.0–24.0%); approximately 2–3× the US general population rate of 6.6%. Anxiety disorders affect an additional ~13.5% on a current-episode basis.
DOI: 10.1093/rheumatology/ket169  ·  PMID: 23661497
[14] Nurmohamed MT et al. "Rheumatoid arthritis: from palliation to remission in two decades." Best Practice & Research: Clinical Rheumatology, 2025. Rheumatoid arthritis patients have cardiovascular risk equivalent to diabetes, including 2× myocardial infarction risk and 70% increased stroke risk vs. matched controls without rheumatoid arthritis. Lymphoma risk elevated up to 26× relative to the general population — driven by cumulative inflammatory burden.
DOI: 10.1016/j.berh.2024.101978 (ScienceDirect)
[15] Yun H et al. "Patterns of biologic use and healthcare resource utilization in rheumatoid arthritis patients newly initiating biologic therapy." Rheumatology International, 2019;39(3):479–489. Rheumatoid arthritis patients accumulate a mean of approximately 20–25 outpatient encounters in the 12 months prior to biologic initiation; ~35% have at least one ED visit in this window.
DOI: 10.1007/s00296-018-4197-8  ·  PMID: 30382378
[16] Dummit LA et al. "Total Knee Arthroplasty: Hospital Costs and Patient Out-of-Pocket Costs." Journal of Orthopaedic Surgery and Research, 2023 (data cited in Sesame Health and KneeReplacementCost.com analyses). Average TKA procedure cost (no complications): $29,300 (range $15,000–$70,000). Average THA: ~$32,000. At 20% commercial coinsurance (KFF 2023 national average), patient OOP per joint: ~$5,860–$6,400. Medicare enrollees without supplemental coverage: ~$1,632–$2,100 per joint (CMS 2024 fee schedule). Uninsured patients bear the full sticker price. Surgery costs represent a one-time capital event, not an annual recurring figure; the calculator amortizes this appropriately when combined with annual drug and productivity costs.
URL: sesamecare.com — TKA cost analysis  ·  KFF 2023 Survey: kff.org/ehbs-2023
[17] Lewis GN et al. "Ninety-day and one-year healthcare utilization and costs after knee arthroplasty." Osteoarthritis and Cartilage, 2019;27(11):1581–1590. Medicare patient OOP for post-TKA care in year 1: $1,342 (predominantly physical therapy: $637). Total first-year patient responsibility including surgical admission: ~$4,293. Commercial insurance patients' PT costs in year 1: $3,200–$9,300 depending on comorbidity burden and recovery protocol (cited in Mira Health 2023 analysis). Nearly all patients attend a mean of 33 PT visits requiring ~36 hours in the first 90 days.
PMC: PMC6750955  ·  DOI: 10.1016/j.joca.2019.06.012
[18] Bansback N et al. "Triage and monitoring of patients with rheumatoid arthritis in routine practice: a claims-based cost comparison." Journal of Rheumatology, 2012;39(4):703–711 (figures corroborated by Neovius M et al., Ann Rheum Dis, 2015;74(2):354–360). Commercial claims analyses consistently report total annual healthcare costs 3–4× higher for biologic-treated rheumatoid arthritis patients compared with those managed on conventional DMARDs alone, driven overwhelmingly by drug acquisition cost rather than medical service use.
DOI: 10.3899/jrheum.110550